| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f834ce5e3653300cfeee6fc9f68468f7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
| filingDate |
1997-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2007-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7daf6062125b1c23dd6278271b62d76d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99744af2893b8757e506c5ae660b0a30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60d00f8009c4817c2c04a63acc4d9a3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb37b882fb6ddb6a24e3cc6676112190 |
| publicationDate |
2007-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0925069-B1 |
| titleOfInvention |
Use of cetrorelix for the treatment of benign prostate hypertrophy and prostate cancer |
| abstract |
A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with α-reductase inhibitors or α-receptor blocking agents. The regimen reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrolix can be administerd with α-reductase inhibitors or α-receptor blocking agents. |
| priorityDate |
1996-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |